FRENKEL JACOB A 4

What Happened
Jacob A. Frenkel, a director of BrainStorm Cell Therapeutics, was granted 200,000 restricted stock units (RSUs) on Feb 26, 2026. The award was reported as acquired at $0.00 (award/grant), so there was no cash purchase. Per the award terms, 50% of the RSUs (100,000 shares) vested on the grant date and the remaining 50% (100,000 shares) vests on the six‑month anniversary, subject to continued service.

Key Details

• Transaction date and type: 2026-02-26 — Award/Grant of 200,000 RSUs at $0.00.
• Vesting: 50% vested on grant date; remaining 50% vests six months after grant (employment condition).
• Shares owned after transaction: Not stated in the provided filing excerpt.
• Filing timing: Form filed May 29, 2026 for a Feb 26, 2026 grant (appears to be filed well after the transaction date).
• Plan: Award granted under the 2014 Global Share Option Plan (per footnote).

Context
RSU awards are compensation, not market purchases or sales; they typically become taxable and transferable only as they vest. The immediate 50% vesting means Frenkel received (or became entitled to) 100,000 shares at grant, with the remainder contingent on continued service through the six‑month vesting date. This type of grant is common for director compensation and does not by itself indicate a buy or sell signal.